Literature DB >> 6318662

Effect of ketoconazole and amphotericin B on encapsulated and non-encapsulated strains of Cryptococcus neoformans.

D Smith, H W McFadden, N G Miller.   

Abstract

Growth inhibition studies were done on an encapsulated and non-encapsulated strain of Cryptococcus neoformans at the minimal inhibitory concentration and one-half the minimal inhibitory concentration of ketoconazole and amphotericin B alone and in combination. Growth of both strains was significantly inhibited by ketoconazole, amphotericin B, and the combined drugs at the minimal inhibitory concentration of each drug over a 5-day period. Calculation of the expected inhibition of growth for both strains with both drugs showed antagonism at 24 h followed by an additive effect and synergy for the remaining 4 days of the assay. Although similar results were obtained for both strains with one-half the minimal inhibitory concentration, an additive effect was observed with the drug combination at 24 h for the encapsulated strain, and an antagonistic effect was observed with the non-encapsulated strain.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6318662      PMCID: PMC185395          DOI: 10.1128/AAC.24.6.851

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Inhibition of ergosterol synthesis in Candida albicans by ketoconazole [proceedings].

Authors:  H Van Den Bossche; G Willemsens; W Cools; F Cornelissen
Journal:  Arch Int Physiol Biochim       Date:  1979-10

2.  In vitro studies of amphotericin B in combination with the imidazole antifungal compounds clotrimazole and miconazole.

Authors:  R F Cosgrove; A E Beezer; R J Miles
Journal:  J Infect Dis       Date:  1978-11       Impact factor: 5.226

Review 3.  Cryptococcosis: current status.

Authors:  M L Littman; J E Walter
Journal:  Am J Med       Date:  1968-12       Impact factor: 4.965

Review 4.  Chemistry and biology of the polyene macrolide antibiotics.

Authors:  J M Hamilton-Miller
Journal:  Bacteriol Rev       Date:  1973-09

5.  Inhibition of potentially pathogenic yeastlike fungi by clotrimazole in combination with 5-fluorocytosine or amphotericin B.

Authors:  W H Beggs; G A Sarosi; N M Steele
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

6.  Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism).

Authors:  G Medoff; G S Kobayashi; C N Kwan; D Schlessinger; P Venkov
Journal:  Proc Natl Acad Sci U S A       Date:  1972-01       Impact factor: 11.205

7.  Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole.

Authors:  J R Graybill; D M Williams; E Van Cutsem; D J Drutz
Journal:  Rev Infect Dis       Date:  1980 Jul-Aug

8.  In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis.

Authors:  H Van den Bossche; G Willemsens; W Cools; F Cornelissen; W F Lauwers; J M van Cutsem
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

9.  Ketoconazole -- a new broad spectrum orally active antimycotic.

Authors:  D Thienpont; J Van Cutsem; F Van Gerven; J Heeres; P A Janssen
Journal:  Experientia       Date:  1979-05-15

10.  Disposition of ketoconazole, an oral antifungal, in humans.

Authors:  C Brass; J N Galgiani; T F Blaschke; R Defelice; R A O'Reilly; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.